Wednesday 6 March
12:00-13:00
Registration
13:00-13:10
Presidential Welcome Address & Welcome of Organizer
13:10-14:30
Session 1: Targeting delivery of RNA Therapeutics
Chair: Ernst Wagner, LMU, Munich
13:10-13:30 Olivia Merkel, LMU, Munich
INV01: Artificial Intelligence for the Design of New RNA Nanocarriers
13:30-13:50 Ulrich Lächelt, University of Vienna
INV02: Xenopeptides for the delivery of CRISPR/Cas9 ribonucleoproteins
13:50-14:10 Christian Plank, Ethris, Munich
INV03: Modulation of host immunity in the airways with interferon lambda encoding mRNA
14:10-14:20 Mina Yazdi, LMU, Munich
OR01: In vivo endothelial cell gene silencing by siRNA-LNPs tuned with lipoamino bundle chemical and ligand targeting
14:20-14:30 Olympia Bikou, LMU, Munich
OR02: Aerosolized gene and oligonucleotide therapy targeting microRNA-224 ameliorates pulmonary hypertension by orchestrating the BMP pathway
14:30-15:00
Session 2: Inflammation therapeutics
Chair: Ulrike Protzer, TUM, Munich
14:30-14:50 Stefan Engelhardt, LMU, Munich
INV05: Inhalation RNA therapeutics targeted to macrophages
14:50-15:00 Lea Krutzke, University of Ulm
OR03: Extracellular vaccine- or virus-derived SARS-CoV-2 spike protein: a potential link between reported pathologies
15:00-15:40
Wolfram Ostertag Lecture
Chair: Manuel Grez
15:00- 15:05 Introduction by chair
15:05-15:40 Dorothee von Laer, Medical University of Innsbruck
INV06: A rhabdovirus for oncolysis and immunotherapy of cancer
15:40-16:10
Coffee Break
16:10-17:50
Session 3: Novel concepts in editing
Chair: Julian Grünewald, TUM Münich
16:10-16:30 Toni Cathomen, University of Freiburg
INV08: New insights in on- and off-target effects of genome editing
16:30-16:50 Zoltan Ivics, PEI, Langen
INV09: Next generation Sleeping Beauty transposases for nonviral engineering of therapeutic cells
16:50-17:10 Frank Buchholz, Dresden University
INV10: Engineering Designer-Recombinases for therapeutic genome editing
17:10-17:30 Angelo Lombardo, SR Tiget, Milan
INV11: Exploiting Targeted Epigenome Editing for Therapeutic Applications.
17:30-17:40 Victor Glaser, Charité University Berlin
OR04: Enhanced safety in multiplex-edited T cells through combined use of distinct CRISPR enzymes for knock-in and base editing
17:40-17:50 Sibtain Haider, University Medical Center, Freiburg
OR05: Peptide-assisted tethering of DNA repair effectors to Cas9 for precise genome editing
17:50-18:40
Session 4: Keynote
Chair: Zoltan Ivics, PEI, Langen
17:50-18:40 Laura Sepp-Lorenzino, Intellia, Boston
INV12: Advances in Therapeutic CRISPR Cas9 Applications
18:40-20:00
Afterglow & posterwalk
THURSDAY 7 March
08:30-09:00
Registration
9:00–10:20
Session 5: Editing cardiomyopathies
Chair: Christian Kupatt, TUM, Munich
9:00-9:20 Julian Grünewald, TUM, Munich
INV13: Engineering CRISPR technologies for application in cardiovascular medicine
9:20-9:40 Mauro Giacca, King's College London
INV14: RNA Therapies for Cardiac Regeneration and Gene Editing
9:40-10:00 Simon Lebek, University Clinic Regensburg
INV15: CRISPR-Cas9 gene editing as a therapy for common cardiovascular diseases
10:00-10:20 Charles Gersbach, Duke University, Durham
INV16: Genome Editing for Duchenne Muscular Dystrophy
10:20-10:50
Coffee break
10:50-12:10
Session 6: New preclinical and clinical cancer concepts
Chair: Roland Rad, TUM, Munich
10:50-11:10 Claudio Mussolino, University of Freiburg
INV17: Multiplexed epigenome editing to protect CAR T cells from cancer-induced activation of inhibitory checkpoints
11:10-11:30 Liane Preußner, BioNTech, Mainz
INV18: BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-Amplifying RNA Vaccine (CARVac)
11:30-11:50 Ben Kleinstiver, Harvard Medical School, Boston
INV19: Engineering Improved CRISPR Technologies
11:50–12:00 Lea-Isabell Schwarze, University Medical Center Hamburg-Eppendorf
OR06: Translation of advanced cell therapies for HIV+ patients
12:00–12:10 Jonas Kath, Charité University Berlin
OR07: CD3-zeta gene editing to reprogram T or NK cells with chimeric antigen receptors
12:10-13:40
Lunch & posters
13:40-14:50
Session 7: Cancer cell and virotherapy
Chair: Dirk Nettelbeck, DKFZ, Heidelberg
13:40-14:00 Alan Melcher, The Institute of Cancer Research, London
INV20: T cell receptor-antigen engagement dynamics with oncolytic virotherapy defines a novel subset of functionally active anti-tumour CD8 cells
14:00-14:20 Per Sonne Holm, Medical University Innsbruck
INV21: Cell cycle inhibition and epigenetic modulation meets YB-1 based virotherapy
14:20-14:40 Guy Ungerechts, NCT, Heidelberg
INV22: Viral Vectors for Cancer Immunotherapy
14:40–14:50 Frederik Wienen, University of Ulm
OR08: An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumour targeting
14:50-15:20
Coffee break
15:20-17:00
Session 8: Novel cell therapeutics
Chair: Florian Bassermann, TUM, Munich
15:20-15:40 Andrea Schmidts, TUM, Munich
INV23: Engineering new CAR-T platforms
15:40-16:00 Christine Spitzweg, LMU, Munich
INV24: The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non‑viral gene therapy.
16:00-16:20 Winfried Wels, GSH, Frankfurt
INV25: CAR-engineered NK cells: Empowering the first line of defense against cancer
16:20-16:40 Evelyn Ullrich, Goethe University Frankfurt
INV26: Engineering of primary CAR-NK cells paves the way for next generation immunotherapies
16:40 -16:50 Kerstin Geiger, University of Freiburg
OR09: Base editing restore cellular phenotype of T cells of patients with Hyper-IgE-Syndrome
16:50-17:00 Jiri Eitler, Dresden University of Technology
OR10: Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss
17:00-18:30
Afterglow & posterwalk
19:00-23:00
Networking event
FriDAY 8 March
08:30-09:00
Registration
9:00–10:40
Session 9: In vivo gene therapeutics
Chair: Stefan Kochanek, University of Ulm
9:00-9:20 Stylianos Michalakis, LMU, Munich
INV27: Development of retina-targeted gene therapy: new concepts and remaining challenges
9:20-9:40 Tarik Bozoglu, TUM, Munich
INV28: Affinity peptide mediated retargeting of AAV9 to cardiac interstitial cells
9:40-10:00 Hildegard Büning, MHH, Hannover
INV29: Tailoring Adeno-associated virus (AAV) vectors for in vivo gene therapy
10:00-10:20 Dirk Grimm, University of Heidelberg
INV30: AAV (finally) flexes its muscles: Evolution and application of myotropic AAV capsid variants
10:20-10:30 Marco Radukic, Bielefeld University
OR11: ITR instability in E. coli? The answer is 42 (°C) for improving quantity and quality of rAAV
10:30-10:40 Ceren Kimna, Helmholtz Center Munich
OR12: Cell Level Imaging of Nucleic Acid Therapeutics in Whole Mouse Bodies
10:40-11:10
Coffee
11:10-11:20
Session 10: Introduction of the National Network Office for Gene and Cell Therapies
11:10-11:20 Elke Luger, National Network Office for Gene and Cell Therapy
The National Network for Gene and Cell Therapies – just another network?
11:20-12:35
Session 11: Young investigator session
Chair: Hildegard Büning, MHH, Hannover
11:20-11:35 Daniela Paasch, MHH, Hannover
OR13: Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19- positive leukemia
11:35-11:50 Samuel Theuerkauf, Paul Ehrlich Institute, Langen
OR14: AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery
11:50-12:05 Juliane Schott, MHH, Hannover
OR15: Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B
12:05-12:20 Martin Bentler, MHH, Hannover
OR16: Modifying immune responses to adeno-associate virus vectors by capsid engineering
12:20-12:35 Max Wichmann, University Medical Center Hamburg-Eppendorf, Hamburg
OR17: Deep characterization and comparison of different retrovirus-like particles preloaded with CRISPR/Cas9 RNPs
12:35-13:15
Session 12: Ethical considerations
Chair: Axel Schambach, Hannover Medical School
12:35-12:55 Klaus Tanner, University of Heidelberg
INV31: Ethics through bureaucracy? The limits of formal rationality
12:55-13:15 Gerd Maass, Roche, Munich
INV33: Challenges and opportunities of CGT - the industrial perspective